| Cat. No. |
Size |
Price |
Figures |
|---|
RP13496-0.2 mg
| 0.2 mg | $ 76.00 | MSDS: 20080909221518 (PDF)
References:
- Rossi NF. Regulation of vasopressin secretion by ETA and ETB receptors in compartmentalized rat hypothalamo-neurohypophysial explants. Am. J. Physiol. Endocrinol. Metab. Apr 2004; 286(4): E535-541.
- Borgheresi RA, et al. Pharmacologic and molecular characterization of the vascular ETA receptor in the venomous snake Bothrops jararaca. Exp. Biol. Med. (Maywood). Jun 2006; 231(6): 729-735.
- Getting SJ, et al. Investigation into the potential anti-inflammatory effects of endothelin antagonists in a murine model of experimental monosodium urate peritonitis. J. Pharmacol. Exp. Ther. Jul 2004; 310(1): 90-97.
|
|---|
| Full Name | |
| Alias |
IRL-1038; IRL1038 |
Sequence
(one-letter code) |
CVYFCHLDIIW |
Sequence
(three-letter code) | {CYS}{VAL}{TYR}{PHE}{CYS}{HIS}{LEU}{ASP}{ILE}{ILE}
{TRP} |
|---|
| Chemical Bridge | Disulfide bridge: Cys1-Cys5 |
|---|
| Description | IRL 1038 is a novel antagonist of the ETB receptor responsible for the release of relaxing factor from the vascular endothelium. The ETB antagonist, IRL-1038, potentiated contractile responses to SRTX-c. |
|---|
| Solubility | Insoluble in water. Dissolve the content with 50-100 ml DMSO - then dilute to any desired concentration with water or buffer. |
|---|
| Formula | C68H92N14O15S2 |
|---|
| M.W. | 1409.7 |
|---|
| Cas | 144602-02-8 |
|---|
| Purity | > 95% |
|---|
| Storage | Store at -20°C. |
| Notes | 3 µM IRL-1038 antagonized the ETB receptor mediated contraction on guinea pig ileal and tracheal smooth muscle without any significant agonistic activity but did not affect the ETA receptor mediated contraction of rat aortic smooth muscle. |
|---|
